Reference Interval:
By report
|
| Interpretive Data: |
The virco®TYPE HIV-1 assay predicts HIV-1 drug resistance based on the nucleic acid sequence of the patient's human immunodeficiency virus. The virco®TYPE HIV-1 analyzes sequences that encompass the entire protease gene and codons 1-335 of the reverse transcriptase gene. Virus from the patient is sequenced at ARUP Laboratories, and the sequence is sent to Virco (vircolab.com) for analysis using the Virtual Phenotype Linear Modeling analysis. This test should be used in conjunction with clinical presentation and other laboratory markers. A patient's response to therapy depends on multiple factors, including patient compliance, percentage of resistant virus population, dosing, and drug pharmacology issues. Resistance interpretations may vary with test method.
According to the Viroseq™ HIV-1 Genotyping System software manual, some insertions or deletions may be difficult to detect using this software. This test may not detect minor HIV-1 populations less than 20 percent of the total population.
The performance characteristics of this test were determined by ARUP Laboratories, Inc.
|
| Note: |
This test may be unsuccessful if the plasma HIV-1 RNA viral load is less than 1,000 HIV-1 RNA copies per mL of plasma.
For a complete list of drugs currently profiled by this assay, please contact ARUP Client Services.
|
| CPT Code(s): |
87900 Phenotype prediction using genotypic bioinformatics; 87901 Genotype analysis by nucleic acid
|
Cross References: |
HIV Drug Resistance (Human Immunodeficiency Virus 1, virco®TYPE)
, HIV Genotype (Human Immunodeficiency Virus 1, virco®TYPE)
|